Navigation Links
Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
Date:6/11/2009

ed products and product candidates that are currently in development; grow product revenue through Cornerstone's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of Cornerstone's currently marketed products, newly acquired products and product candidates.

Important Information

Cornerstone has filed a proxy statement and other documents regarding the transaction described in this press release with the Securities and Exchange Commission. Security holders are urged to read the proxy statement carefully because it contains important information about Cornerstone and the transaction with Chiesi Farmaceutici SpA. A definitive proxy statement will be sent to stockholders of Cornerstone seeking their approval of the transaction. Investors and security holders may obtain a free copy of the definitive proxy statement (when available) and other documents filed by Cornerstone with the SEC at the SEC's website at www.sec.gov or from Cornerstone's website at www.crtx.com. The definitive proxy statement (when available) and other relevant documents may also be obtained free of cost by directing a request to Cornerstone Therapeutics Inc., 1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518, attention: Chief Financial Officer.

Participants in Solicitation

Cornerstone and its directors, members of management and other employees may be deemed to be participants in the solicitation of proxies from the stockholders of Cornerstone in connection with the transaction. Information about Cornerstone and its directors and executive officers can be found in Cornerstone's proxy statement and Annual Report on Form 10-K for the year ended December 31, 2008 previously filed with the SEC. Additional in
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
3. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
4. Cornerstone Therapeutics Announces New Board of Directors
5. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
6. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
7. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Cornerstone Therapeutics Announces Management Change
10. TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Hope For The Warriors® is ... to be hosted in Boston, Massachusetts on Sunday, November ... This signature event honors the courage of our wounded ... fallen. Proceeds from the evening will benefit Hope For ... sense of self, restoring the family unit, and restoring ...
(Date:9/23/2014)... Ithaca, New York (PRWEB) September 23, 2014 ... vulvodynia, interstitial cystitis, pudendal neuralgia, and other chronic pelvic or ... to lasting relief. , According to the Gallup poll, 1 ... suffer from chronic pelvic pain. Many of those women ... with their healthcare providers. The type of pain varies ...
(Date:9/23/2014)... 2014 People across Minnesota acknowledge that ... choices, but barriers are more prominent in the state’s ... Center for Prevention at Blue Cross and Blue Shield ... to healthy, affordable food and a lack of places ... About 60 percent of rural Minnesotans who responded to ...
(Date:9/23/2014)... 23, 2014). Researchers from the University of ... Krischek, investigated gene expression in normal vestibular nerves ... made: 1) there is negligible difference between VSs ... neurofibromatosis Type 2 (NF2), a genetic disorder; and ... tumors may be an excellent therapeutic target. Detailed ...
(Date:9/23/2014)... "Bee Towers” was featured on NewsWatch as part of its ... gadgets and services available to consumers. Mallory Sofastaii, a host ... and shared with viewers how it can hold tablets ... in the United States continue to climb. According to ... , For consumers who own a tablet but want ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3Health News:Mind Body Expert Launches Pelvic Pain Relief Program 2Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 2Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 3Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 4Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 5Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 2Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 3Health News:“Bee Towers”, a Floor Standing Tablet Holder by XAR Motion, was Featured on NewsWatch, a National Television Show, This Month 2
... EUR10.8 Million in ... ... (Nasdaq: CHDX ), an independent American provider of international,healthcare services ... that it has signed two contracts for the,supply of EUR10.8 million ...
... Because of the demographic changes, there will be a ... in 2004, the medical costs for the care of ... In their original article in the current edition of ... 105[26]: 467󈞵), the neurologist Tobias Neumann-Haefelin of the Johann ...
... in #1 respiratory hospital ranking, DENVER, July ... traditional boundaries of respiratory medicine into,exciting new areas ... Center will become National Jewish Health, effective immediately., ... put, this isn,t just about a name change. ...
... series of online NHS Health Guides,for people with long-term ... NHS Choices http://www.nhs.uk , These online guides ... diagnosis, and through to how to live and self ... be rolling out more,guides from the 60 most common ...
... BROOK, Ill. C JULY 11, 2008 -- A study ... of Radiology,s (ACR) CT colonography guidelines recommending that polyps ≤ ... applying them to an endoscopic database that collected information about ... also recommend that patients with one or two polyps 6 ...
... Placing 15 of its 16 Ranked Specialties Ahead of All ... Clinic Specialties Rated Among Nation,s Top Ten, ... Clinic,s cardiac care has been ranked No. 1 in the nation,according ... The survey recognizes Cleveland Clinic as one of the nation,s ...
Cached Medicine News:Health News:Chindex International, Inc. Announces CDC Contract Signing 2Health News:Chindex International, Inc. Announces CDC Contract Signing 3Health News:Chindex International, Inc. Announces CDC Contract Signing 4Health News:Bold Evolution Transforms National Jewish Medical and Research Center to National Jewish Health 2Health News:Bold Evolution Transforms National Jewish Medical and Research Center to National Jewish Health 3Health News:Online NHS Health Guides for Long-Term Conditions Released on NHS Choices 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 3Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 4Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 2Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 3
(Date:9/23/2014)... 2014 Enable Injections , developer of ... it easy and nearly painless for patients to self-inject ... has been named winner of the ,Buzz of BIO ... biotech sector.    Enable is one of only ... number of votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... Sept. 23, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... to its Scientific Advisory Board.  The new members are ... , PhD. Dr. Acker is a Senior ...
(Date:9/23/2014)... LONDON , September 23, 2014 ... pharmaceutical assets, announces the appointment of Jarrod ... role, Mr Longcor is responsible for structuring, negotiating ... financial investments, as well as providing management and ... member of the Executive leadership team. ...
Breaking Medicine Technology:Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... May 26, 2011 Rigel Pharmaceuticals, Inc. ... of its previously announced underwritten public offering of 16,300,000 ... of $8.00 per share to the public. The gross ... be approximately $130,400,000, before deducting underwriting discounts and commissions, ...
... Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP ) ... amount of senior unsecured notes. The notes will be unsecured, ... certain of the Company,s subsidiaries.   Endo intends ... cash on hand and borrowings under its new credit facility, ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes 2
... ENA Multiparameter Kit is designed ... six of the most common ... unique quality control system. The ... well in each strip gives ...
Inquire...
Microalbumin Linearity Control...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
Medicine Products: